
TransCode Therapeutics fell 86.0% from $9.41 to $1.32, behind the S&P 500's +11.2%. Its worst day was Jul 24 (−16.5%), and its low came Nov 13 at $1.32.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
TransCode Therapeutics shares rose 20.7%, while the S&P 500 rose 0.2%.
+20.7% · S&P 500 +0.2%
TransCode Therapeutics closed at its highest level of the year, 31.1% above where the year started.
Story events cover the past 12 months · Times ET
+25.0%, the year's best day · S&P 500 +0.5%
TransCode Therapeutics shares rose 20.3%, while the S&P 500 rose 0.5%.
+20.3% · S&P 500 +0.5%
EPS of $-18.10 was reported on $0.00 revenue.
−2.4% · S&P 500 +0.2%
EPS of $-21.28 was reported on $0.00 revenue.
−9.3% · S&P 500 −0.1%
TransCode Therapeutics shares rose 15.9%, while the S&P 500 rose 0.4%.
+15.9% · S&P 500 +0.4%
TransCode Therapeutics shares rose 23.2%, while the S&P 500 fell 0.1%.
+23.2% · S&P 500 −0.1%
TransCode Therapeutics shares rose 21.8%, while the S&P 500 rose 0.8%.
+21.8% · S&P 500 +0.8%
TransCode Therapeutics shares fell 16.5%, while the S&P 500 rose 0.1%.
−16.5%, the year's worst day · S&P 500 +0.1%
EPS of $-7.17 was reported on $0.00 revenue.
−3.7% · S&P 500 −0.5%
Where it ended: a close of $1.32 on Nov 13, 2026. Up next: Q3 2026 earnings on Feb 13, 2027.
Nothing in the past 12 months.
All RNAZ analyst actionsNothing in the past 12 months.
All RNAZ dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RNAZ and SPY from Benzinga historical bars. Not investment advice.